This article is for informational purposes only and does not constitute medical advice. Superpower Health facilitates access to bremelanotide (PT-141) through licensed healthcare providers and compounding pharmacy partners. Always consult a qualified healthcare provider before starting any prescription compound.
Viagra changed how medicine approaches erectile dysfunction. It did not change how medicine approaches desire. For the estimated 43% of women and 31% of men who experience sexual dysfunction rooted in drive rather than blood flow, the pharmacological options have been limited until recently.
PT-141 targets the brain rather than blood vessels. Here is what that means, who it is prescribed for, and what the clinical evidence supports.
Key Takeaways
- Regulatory Status: FDA-approved in June 2019 as Vyleesi (bremelanotide injection, 1.75 mg) for hypoactive sexual desire disorder (HSDD) in premenopausal women. Also available as compounded bremelanotide through licensed 503A pharmacies with a patient-specific prescription. Compounded formulations such as sublingual troches use a different route of administration from the FDA-approved Vyleesi injection and are not considered "essentially a copy" under FDA guidance.
- Research Stage: Phase 3 RCT evidence (RECONNECT program); FDA-approved for HSDD
- Availability: Prescription only through Superpower's licensed provider network and compounding pharmacy partners
- Prescribing information: View full prescribing information — Vyleesi (DailyMed)
- How it works: Activates melanocortin receptors (primarily MC4R) in the central nervous system to modulate sexual desire and arousal signaling.
- What the research shows: In the RECONNECT Phase 3 RCT (N=1,267 premenopausal women), bremelanotide 1.75 mg SC administered on demand over 24 weeks improved FSFI desire domain scores by 0.35 points more than placebo (P<0.001) and reduced FSDS-DAO distress scores by 0.33 points more than placebo (P<0.001).
What Is PT-141 (Bremelanotide)?
Bremelanotide (marketed as Vyleesi; also known in peptide communities as PT-141) is a synthetic cyclic heptapeptide melanocortin receptor agonist. It is structurally derived from alpha-melanocyte-stimulating hormone (alpha-MSH) and binds primarily to melanocortin receptor subtypes MC1R, MC3R, and MC4R. Its primary clinical action is activation of MC4R in the hypothalamus and limbic system, which modulates the neural circuitry underlying sexual desire and arousal. It does not act on vascular smooth muscle, which is what distinguishes it mechanistically from PDE5 inhibitors such as sildenafil and tadalafil.
PT-141 was the compound designation used during the research and development phase before brand-name approval. Both names refer to the same molecule. Bremelanotide received FDA approval in June 2019 as Vyleesi for the treatment of hypoactive sexual desire disorder (HSDD) in premenopausal women. It is the second FDA-approved pharmacological treatment for HSDD, following flibanserin (Addyi) in 2015, and the first approved for on-demand use. Bremelanotide is administered as a subcutaneous injection 45 minutes before anticipated sexual activity. It is also available as a compounded formulation through licensed 503A pharmacies.
What Bremelanotide May Support
1. Sexual Desire in Women With HSDD
The pivotal evidence for bremelanotide comes from the RECONNECT clinical program, comprising two Phase 3 RCTs published by Kingsberg and colleagues in Obstetrics and Gynecology in 2019. The combined trial enrolled 1,267 premenopausal women with a diagnosis of HSDD. Participants received bremelanotide 1.75 mg subcutaneously or placebo on demand over 24 weeks. Across the integrated analysis (N=1,202 efficacy population), bremelanotide improved the Female Sexual Function Index (FSFI) desire domain score by 0.35 points more than placebo (P<0.001; study 301: +0.30, P<0.001; study 302: +0.42, P<0.001) and reduced the Female Sexual Distress Scale-Desire/Arousal/Orgasm (FSDS-DAO) item 13 score by 0.33 points more than placebo (P<0.001; study 301: −0.37, P<0.001; study 302: −0.29, P=0.005). A 2020 review by Mayer and Lynch in Annals of Pharmacotherapy, which evaluated two Phase 2 and two Phase 3 trials of bremelanotide (approximately 1,594 participants across the Phase 2b dose-finding trial and Phase 3 RECONNECT program) identified through searches of Medline, SCOPUS, and EMBASE, confirmed statistically significant improvements in both endpoints but noted that the absolute magnitude of clinical benefit may be modest, and a 2025 narrative review by Barakeh and Mdaihly in the same journal advised clinical caution given the limited effect size and potential adverse effects. A re-analysis of the Phase 3 data published by Spielmans in a 2021 Journal of Sex Research article raised concerns about selective outcome reporting. These counterpoints are important context when evaluating the clinical evidence.
2. Reduction in Distress Related to Low Sexual Desire
The FDA's approval of bremelanotide was anchored specifically on two co-primary endpoints: improvement in sexual desire (measured by FSFI desire domain) and reduction in desire-related distress (measured by FSDS-DAO item 13). The distress endpoint is clinically significant because HSDD is defined not only by low desire but by the personal distress that accompanies it. A 52-week open-label extension of the RECONNECT trial published by Simon, Kingsberg, and colleagues in Obstetrics and Gynecology in 2019 enrolled 684 participants who received bremelanotide 1.75 mg SC as needed without a placebo comparator arm. Among those who had received bremelanotide in the core phase, FSFI desire domain scores increased by 1.25 to 1.30 points from baseline and FSDS-DAO item 13 scores decreased by 1.4 to 1.7 points from baseline at 52 weeks, with no new safety signals emerging in longer-term use.
3. Sexual Arousal Processing in Women With HSDD
A 2022 double-blind, placebo-controlled crossover study by Thurston, Hunjan, and colleagues in the Journal of Clinical Investigation (N=31 premenopausal women with HSDD) administered bremelanotide 1.75 mg SC at two study visits with fMRI scanning at each session to evaluate the drug's central mechanism. MC4R agonism significantly enhanced cerebellar and supplementary motor area activation in response to erotic visual stimuli compared with placebo (Z=2.3, P<0.05), deactivated the secondary somatosensory cortex, and increased amygdala-insula functional connectivity (F(1,30)=5.55, P=0.025). The authors interpreted this as bremelanotide reducing the cognitive-emotional barriers to sexual engagement rather than simply amplifying a peripheral signal. This mechanism helps explain why bremelanotide may be effective in women whose low desire is rooted in inhibitory rather than purely physiological factors.
4. Erectogenic Effects in Men (Preclinical and Early-Phase Data)
Two early-phase RCTs examined PT-141 in male populations. Diamond, Earle, and colleagues published a 2004 double-blind, placebo-controlled study in the International Journal of Impotence Research evaluating intranasal PT-141 at doses up to 20 mg in 32 healthy males (without visual sexual stimulation) and in men with mild-to-moderate erectile dysfunction (with visual sexual stimulation), finding a statistically significant erectogenic response on RigiScan at doses greater than 7 mg, with onset of the first erection occurring in approximately 30 minutes and the 20 mg dose producing significantly greater duration of base rigidity of 80% or above compared to placebo. Rosen, Diamond, and colleagues published a separate 2004 double-blind, placebo-controlled crossover study in the same journal evaluating subcutaneous PT-141 at doses ranging from 0.3 to 10 mg in healthy males and at 4 mg and 6 mg in 25 men with erectile dysfunction who achieved erections suitable for penetration 50% or less of the time on 100 mg sildenafil, finding that mean duration of base rigidity at 80% or above was 14 minutes at the 4 mg dose and 17 minutes at the 6 mg dose compared with 2 minutes for placebo on RigiScan over a single-dose session. A 2006 double-blind, placebo-controlled crossover study by Diamond, Earle, and colleagues published in the Journal of Sexual Medicine enrolled 18 premenopausal women with female sexual arousal disorder who each received a single intranasal dose of 20 mg bremelanotide or placebo at two in-clinic sessions, finding that significantly more women reported moderate or high sexual desire after bremelanotide versus placebo (P=0.01) and that among those who attempted intercourse within 24 hours, significantly more were satisfied with their level of arousal after bremelanotide (P=0.03). These trials support the biological plausibility of bremelanotide for male sexual dysfunction, but no Phase 3 trials in men have been conducted. Bremelanotide is not FDA-approved for any indication in men. No other uses have been approved by the FDA for bremelanotide, and its safety and efficacy for any use other than HSDD in premenopausal women have not been established through adequate and well-controlled clinical trials reviewed by the FDA.
5. Sexual Desire in Women With Female Sexual Arousal Disorder
A dose-finding RCT published by Clayton, Althof, and colleagues in Women's Health in 2016 randomized 327 premenopausal women with female sexual dysfunctions to placebo or subcutaneous bremelanotide at 0.75 mg, 1.25 mg, or 1.75 mg as needed over 12 weeks. For the pooled 1.25/1.75 mg doses versus placebo, mean changes from baseline were +0.7 versus +0.2 satisfying sexual events per month (P=0.02), +3.6 versus +1.9 on the FSFI total score (P=0.002), and −11.1 versus −6.8 on the FSDS-DAO total score (P=0.001), with nausea, flushing, and headache as the most common adverse effects. This study established the dose-response relationship that informed the Phase 3 protocol. A preclinical CNS mechanism review published by Pfaus and Giuliano in the Journal of Sexual Medicine in 2007 provided foundational context on how bremelanotide selectively increases sexual solicitation through a central, not peripheral, mechanism — a distinction relevant to understanding how it differs from PDE5 inhibitors in both mechanism and patient population.
PT-141 vs. PDE5 Inhibitors (Viagra/Cialis): Key Differences
Bremelanotide activates brain-based melanocortin receptors; PDE5 inhibitors (sildenafil, tadalafil) act peripherally on vascular smooth muscle. This is a mechanistic distinction with direct clinical implications.
PDE5 inhibitors work by preventing the breakdown of cyclic GMP (cGMP) in smooth muscle cells, which sustains vasodilation and blood flow to genital tissues. They require sexual arousal to be present and operate primarily on the vascular response to desire. They address the physical mechanics of erection or engorgement — not the desire signal that precedes them. Bremelanotide acts on the central nervous system, specifically on the melanocortin pathway in the hypothalamus and limbic system, where sexual motivation is generated. It modulates desire and arousal as neural phenomena, not blood flow events. A comprehensive review published by Edinoff, Sanders, and colleagues in Neurology International in 2022 confirmed this mechanistic distinction in a full account of bremelanotide's pharmacology.
The practical implication is that the two compound classes address different components of sexual dysfunction. PDE5 inhibitors are appropriate when the dysfunction is primarily vascular (impaired engorgement or erection despite normal desire). Bremelanotide is indicated for low desire as the primary complaint, where blood flow is not the limiting factor. a 2025 review in Expert Opinion on Pharmacotherapy by Ila and Pozzi reviewed the landscape of peptides for erectile dysfunction, noting that compounds acting through distinct mechanisms from PDE5 inhibitors are particularly relevant for patients who do not respond to that class or whose dysfunction is desire-based. Cross-compound comparisons should be interpreted with attention to the specific populations, endpoints, and study designs involved.
Biomarkers to Monitor With Bremelanotide
A licensed provider will determine appropriate monitoring. Bremelanotide's primary action is central nervous system-based, which means the monitoring focus is on cardiovascular safety, hormonal context, and general metabolic baseline rather than a single primary biomarker. The following are clinically relevant:
- Blood pressure (resting): Bremelanotide is associated with small, transient increases in blood pressure following administration, as documented in a 2017 randomized, double-blind, placebo-controlled ambulatory monitoring study by White and Myers in the Journal of Hypertension (N=397 premenopausal women; bremelanotide 0.75, 1.25, or 1.75 mg SC). The 1.75 mg dose produced a mean systolic increase of approximately 3 mmHg versus placebo in the 0-to-4-hour post-dose window, resolving within 12 hours, accompanied by a compensatory heart rate reduction of approximately 4.7 bpm. Pre-existing hypertension is a contraindication to use. Providers evaluate blood pressure at baseline and may advise against use in individuals with poorly controlled or uncontrolled hypertension.
- Estradiol: Bremelanotide is FDA-approved specifically for premenopausal women. Baseline estradiol status is relevant to clinical context — providers use hormonal baseline to confirm premenopausal status and to rule out hormonal causes of low desire (such as early perimenopause) that might warrant a different approach.
- Total and free testosterone: Low testosterone is associated with reduced sexual desire in both women and men. Baseline testosterone helps providers understand whether a hormonal deficit is contributing to HSDD alongside or independently of melanocortin pathway dysfunction. This is particularly relevant in women with low desire associated with surgical menopause or hormonal contraception.
- Prolactin: Elevated prolactin (hyperprolactinemia) is a recognized endocrine cause of low libido and sexual dysfunction in both sexes. Prolactin assessment at baseline rules out a treatable endocrine cause before attributing low desire to HSDD.
- SHBG (sex hormone binding globulin): SHBG modulates the bioavailability of sex hormones including testosterone and estradiol. Elevated SHBG reduces free hormone levels and can contribute to low desire independently of total hormone levels. SHBG is commonly evaluated alongside testosterone and estradiol in the hormonal workup for sexual dysfunction.
- Complete metabolic panel (CMP): Covers liver and kidney function. Relevant to baseline safety assessment for any prescription compound. Nausea is among the most common bremelanotide adverse effects and may prompt GI-focused monitoring in some individuals.
- TSH (thyroid-stimulating hormone): Thyroid dysfunction (both hypothyroidism and hyperthyroidism) can impair sexual function through multiple pathways including fatigue, mood disruption, and hormonal interference. Ruling out thyroid abnormality is standard in a comprehensive sexual dysfunction workup.
Blood pressure, estradiol, total testosterone, and prolactin are the core markers for a comprehensive hormonal and cardiovascular baseline before bremelanotide therapy. Establishing these baselines helps identify treatable endocrine causes of low desire, confirms candidacy, and supports individualized clinical decision-making. A provider will determine the appropriate scope of baseline testing. Relevant biomarkers for libido and hormonal balance extend beyond a single marker.
What Bremelanotide Is Typically Prescribed For
Bremelanotide (Vyleesi) is FDA-approved for the treatment of HSDD in premenopausal women. Providers evaluate candidates based on a clinical diagnosis of HSDD, defined as persistently low sexual desire causing personal distress, not attributable to a co-existing medical condition, psychiatric disorder, relationship problem, medication effect, or hormonal abnormality that would explain the symptom more parsimoniously. Key evaluation criteria include a full sexual function history, hormonal baseline (estradiol, testosterone, prolactin, SHBG), thyroid function, and a review of medications that may suppress desire (including certain antidepressants, hormonal contraceptives, and antihypertensives). Bremelanotide requires a prescription from a licensed provider. Superpower facilitates access through its licensed provider network and compounding pharmacy partners.
Who Should Not Use Bremelanotide
A licensed provider will evaluate individual risk factors before prescribing. The following are contraindications or conditions requiring additional clinical scrutiny, based on the Vyleesi FDA prescribing information and published safety data:
- Uncontrolled hypertension or known cardiovascular disease — bremelanotide causes transient blood pressure increases that may be clinically significant in individuals with pre-existing cardiovascular risk
- High cardiovascular risk profile (multiple risk factors for major adverse cardiovascular events) — the prescribing information advises against use in this population due to the transient hemodynamic effects
- Postmenopausal women — bremelanotide is FDA-approved only for premenopausal women with HSDD; it has not been studied for efficacy and safety in postmenopausal populations
- Pregnancy or breastfeeding — safety has not been established; women who could become pregnant should use contraception during bremelanotide use
- Known hypersensitivity to bremelanotide or any component of the Vyleesi formulation
- Concurrent use of oral naltrexone — bremelanotide may significantly reduce the systemic exposure of orally administered naltrexone by slowing gastric motility, potentially compromising naltrexone therapy in patients being treated for alcohol or opioid dependence
- Individuals who require consistent blood pressure control for cardiovascular management — the transient BP elevation may complicate management
A licensed provider will evaluate individual risk factors, medication interactions, and hormonal status before prescribing bremelanotide.
Side Effects and Safety Considerations
Bremelanotide's safety profile is well-characterized through the RECONNECT Phase 3 trials (N=1,267) and the 52-week open-label extension. Most adverse effects are dose-dependent and time-limited, resolving within hours of administration.
Common (reported in clinical studies):
- Nausea — the most frequently reported adverse effect; occurred in 40.0% of bremelanotide 1.75 mg recipients versus 1.3% on placebo in the Phase 3 RECONNECT trials (N=1,247 safety population) and in 40.4% of participants (N=684) in the 52-week open-label extension; typically onset within 30 minutes of dosing with a median duration of 2.4 hours; approximately 98% of cases were mild to moderate in severity
- Flushing — transient warmth or redness, particularly of the face; generally mild
- Injection-site bruising, pain, or erythema — common with subcutaneous administration; typically resolves within hours
- Headache — reported in approximately 9% of bremelanotide 1.75 mg recipients versus 5.6% on placebo in the Phase 3 RECONNECT trials (N=1,267)
Less common but reported:
- Transient blood pressure increase — in a randomized ambulatory monitoring study of 397 premenopausal women by White and Myers, bremelanotide 1.75 mg produced a mean systolic increase of approximately 2.5 to 3 mmHg versus placebo with peak effect in the 0-to-4-hour post-dose window, resolving within 12 hours; more pronounced in some individuals; contraindicated in uncontrolled hypertension (contact provider if blood pressure measurements are persistently elevated)
- Hyperpigmentation of the face, breasts, and gums with chronic use — related to bremelanotide's melanocortin receptor activity at MC1R (which governs pigmentation); risk increases with frequent use; the prescribing information limits use to no more than 8 doses per month to reduce hyperpigmentation risk, with no more than one dose per 24 hours
- Vomiting — associated with the nausea response in some patients; an antiemetic taken prior to bremelanotide may be considered per provider guidance
Is Bremelanotide Legal?
As of April 2026, bremelanotide is FDA-approved as Vyleesi (1.75 mg subcutaneous injection) for HSDD in premenopausal women. No other uses have been approved by the FDA. The safety and efficacy of bremelanotide for any use other than the approved HSDD indication in premenopausal women have not been established through adequate and well-controlled clinical trials reviewed by the FDA.
Bremelanotide is also available as a compounded formulation through licensed 503A compounding pharmacies with a patient-specific prescription from a licensed provider. The FDA-approved Vyleesi product and compounded bremelanotide are distinct from one another in terms of regulatory oversight: Vyleesi is subject to full FDA manufacturing standards; compounded bremelanotide is prepared under Section 503A compounding law. Superpower facilitates access to both through its licensed provider network.
Bremelanotide is not on the 2026 WADA Prohibited List by name. Athletes subject to anti-doping testing should nonetheless consult their governing body or a qualified anti-doping advisor, as WADA's prohibited list includes broad catch-all categories for peptides and peptide hormones that may encompass melanocortin agonists.
Understanding Your Baseline Before Starting Bremelanotide
Sexual dysfunction has multiple contributing causes, and hormonal and endocrine abnormalities can present identically to primary HSDD. Establishing a baseline that includes estradiol, testosterone, prolactin, SHBG, and thyroid function before starting bremelanotide is clinically important for two reasons: it rules out treatable endocrine causes that may respond to a different approach, and it provides a reference point for evaluating response over time. Blood pressure confirmation at baseline is essential given bremelanotide's transient hemodynamic effects.
That principle — test first, then decide — is central to Superpower's approach to preventive health: the belief that every clinical decision should be grounded in what your bloodwork actually shows, not in symptoms alone. Understanding your hormonal baseline is the first step.
Frequently Asked Questions
How does PT-141 work differently from Viagra?
Bremelanotide (PT-141) activates melanocortin receptors in the hypothalamus and limbic system to modulate sexual desire as a brain-based signal. Viagra (sildenafil) inhibits PDE5 in vascular smooth muscle to maintain blood flow to genital tissue. Bremelanotide targets desire and arousal centrally; sildenafil targets the physical vascular response to desire. They act on different systems, address different components of sexual function, and are used in different patient populations.
Can women use PT-141?
Yes. Bremelanotide is FDA-approved specifically for use in premenopausal women with hypoactive sexual desire disorder (HSDD). The pivotal RECONNECT Phase 3 trials were conducted exclusively in premenopausal women (N=1,267). The compound has also been studied in early-phase trials for female sexual arousal disorder. Bremelanotide is not FDA-approved for use in postmenopausal women.
How quickly does PT-141 take effect?
Bremelanotide is typically administered subcutaneously 45 minutes before anticipated sexual activity, based on the pharmacokinetic profile established in the RECONNECT trials. Peak plasma concentrations occur approximately 1 hour after subcutaneous injection. Individual onset may vary. The compound should not be administered more than once per 24-hour period.
What are the side effects of PT-141?
The most common side effects reported in the RECONNECT Phase 3 trials were nausea (approximately 40% of recipients), flushing, headache, and injection-site reactions. A transient increase in blood pressure occurs within 12 hours of injection in most users and resolves within 12 hours. Hyperpigmentation of the face, breasts, and gums has been reported with chronic or frequent use. Vomiting occurred in a subset of those who experienced nausea.
Is PT-141 FDA-approved?
Bremelanotide is FDA-approved as Vyleesi (1.75 mg subcutaneous injection) for HSDD in premenopausal women. This is the only FDA-approved indication. It has not been approved for use in men or in postmenopausal women. Compounded bremelanotide is also available through licensed 503A pharmacies with a patient-specific prescription, and is distinct from the FDA-approved Vyleesi product in terms of regulatory oversight.
Can you get PT-141 without a prescription?
No. Bremelanotide is a prescription-only compound in all its forms. Vyleesi requires a prescription from a licensed provider. Compounded bremelanotide also requires a patient-specific prescription from a licensed provider and is dispensed only by licensed 503A compounding pharmacies. It is not available over the counter. Superpower facilitates access through its licensed provider network and compounding pharmacy partners.
What is the difference between Vyleesi and compounded bremelanotide?
Vyleesi is the FDA-approved brand-name product (1.75 mg subcutaneous injection) manufactured under full FDA quality and manufacturing standards. Compounded bremelanotide is prepared by licensed 503A compounding pharmacies under Section 503A of the Federal Food, Drug, and Cosmetic Act, with a patient-specific prescription. The two have the same active compound but differ in regulatory oversight, manufacturing standards, and potentially in available doses or formulation options. A licensed provider can advise on which form is appropriate for a given clinical situation.
IMPORTANT SAFETY INFORMATION
Bremelanotide is FDA-approved as Vyleesi for hypoactive sexual desire disorder (HSDD) in premenopausal women. Compounded PT-141 (bremelanotide) is NOT the FDA-approved product and has not been reviewed by the FDA for safety or efficacy. Compounded PT-141 may only be dispensed upon a prescriber's patient-specific determination that a change from the FDA-approved Vyleesi product is clinically necessary. Superpower is a technology platform; Superpower does not prescribe or dispense medications.
Contraindications: uncontrolled hypertension or cardiovascular disease; postmenopausal women (not studied); pregnancy or breastfeeding; concurrent use of oral naltrexone.
Warnings: transient blood pressure increase (~3 mmHg systolic, resolving within 12 hours); nausea (reported in 40% of clinical trial participants); hyperpigmentation risk with frequent use (max 8 doses/month).
Common side effects: nausea, flushing, headache, injection site reactions.
Full prescribing information on the FDA-approved product (Vyleesi) at dailymed.nlm.nih.gov.
This article is for informational purposes only and does not constitute medical advice. Superpower Health facilitates access to bremelanotide (PT-141) through licensed healthcare providers and compounding pharmacy partners. Always consult a qualified healthcare provider before starting any prescription compound.
Viagra changed how medicine approaches erectile dysfunction. It did not change how medicine approaches desire. For the estimated 43% of women and 31% of men who experience sexual dysfunction rooted in drive rather than blood flow, the pharmacological options have been limited until recently.
PT-141 targets the brain rather than blood vessels. Here is what that means, who it is prescribed for, and what the clinical evidence supports.
Key Takeaways
- Regulatory Status: FDA-approved in June 2019 as Vyleesi (bremelanotide injection, 1.75 mg) for hypoactive sexual desire disorder (HSDD) in premenopausal women. Also available as compounded bremelanotide through licensed 503A pharmacies with a patient-specific prescription. Compounded formulations such as sublingual troches use a different route of administration from the FDA-approved Vyleesi injection and are not considered "essentially a copy" under FDA guidance.
- Research Stage: Phase 3 RCT evidence (RECONNECT program); FDA-approved for HSDD
- Availability: Prescription only through Superpower's licensed provider network and compounding pharmacy partners
- Prescribing information: View full prescribing information — Vyleesi (DailyMed)
- How it works: Activates melanocortin receptors (primarily MC4R) in the central nervous system to modulate sexual desire and arousal signaling.
- What the research shows: In the RECONNECT Phase 3 RCT (N=1,267 premenopausal women), bremelanotide 1.75 mg SC administered on demand over 24 weeks improved FSFI desire domain scores by 0.35 points more than placebo (P<0.001) and reduced FSDS-DAO distress scores by 0.33 points more than placebo (P<0.001).
What Is PT-141 (Bremelanotide)?
Bremelanotide (marketed as Vyleesi; also known in peptide communities as PT-141) is a synthetic cyclic heptapeptide melanocortin receptor agonist. It is structurally derived from alpha-melanocyte-stimulating hormone (alpha-MSH) and binds primarily to melanocortin receptor subtypes MC1R, MC3R, and MC4R. Its primary clinical action is activation of MC4R in the hypothalamus and limbic system, which modulates the neural circuitry underlying sexual desire and arousal. It does not act on vascular smooth muscle, which is what distinguishes it mechanistically from PDE5 inhibitors such as sildenafil and tadalafil.
PT-141 was the compound designation used during the research and development phase before brand-name approval. Both names refer to the same molecule. Bremelanotide received FDA approval in June 2019 as Vyleesi for the treatment of hypoactive sexual desire disorder (HSDD) in premenopausal women. It is the second FDA-approved pharmacological treatment for HSDD, following flibanserin (Addyi) in 2015, and the first approved for on-demand use. Bremelanotide is administered as a subcutaneous injection 45 minutes before anticipated sexual activity. It is also available as a compounded formulation through licensed 503A pharmacies.
What Bremelanotide May Support
1. Sexual Desire in Women With HSDD
The pivotal evidence for bremelanotide comes from the RECONNECT clinical program, comprising two Phase 3 RCTs published by Kingsberg and colleagues in Obstetrics and Gynecology in 2019. The combined trial enrolled 1,267 premenopausal women with a diagnosis of HSDD. Participants received bremelanotide 1.75 mg subcutaneously or placebo on demand over 24 weeks. Across the integrated analysis (N=1,202 efficacy population), bremelanotide improved the Female Sexual Function Index (FSFI) desire domain score by 0.35 points more than placebo (P<0.001; study 301: +0.30, P<0.001; study 302: +0.42, P<0.001) and reduced the Female Sexual Distress Scale-Desire/Arousal/Orgasm (FSDS-DAO) item 13 score by 0.33 points more than placebo (P<0.001; study 301: −0.37, P<0.001; study 302: −0.29, P=0.005). A 2020 review by Mayer and Lynch in Annals of Pharmacotherapy, which evaluated two Phase 2 and two Phase 3 trials of bremelanotide (approximately 1,594 participants across the Phase 2b dose-finding trial and Phase 3 RECONNECT program) identified through searches of Medline, SCOPUS, and EMBASE, confirmed statistically significant improvements in both endpoints but noted that the absolute magnitude of clinical benefit may be modest, and a 2025 narrative review by Barakeh and Mdaihly in the same journal advised clinical caution given the limited effect size and potential adverse effects. A re-analysis of the Phase 3 data published by Spielmans in a 2021 Journal of Sex Research article raised concerns about selective outcome reporting. These counterpoints are important context when evaluating the clinical evidence.
2. Reduction in Distress Related to Low Sexual Desire
The FDA's approval of bremelanotide was anchored specifically on two co-primary endpoints: improvement in sexual desire (measured by FSFI desire domain) and reduction in desire-related distress (measured by FSDS-DAO item 13). The distress endpoint is clinically significant because HSDD is defined not only by low desire but by the personal distress that accompanies it. A 52-week open-label extension of the RECONNECT trial published by Simon, Kingsberg, and colleagues in Obstetrics and Gynecology in 2019 enrolled 684 participants who received bremelanotide 1.75 mg SC as needed without a placebo comparator arm. Among those who had received bremelanotide in the core phase, FSFI desire domain scores increased by 1.25 to 1.30 points from baseline and FSDS-DAO item 13 scores decreased by 1.4 to 1.7 points from baseline at 52 weeks, with no new safety signals emerging in longer-term use.
3. Sexual Arousal Processing in Women With HSDD
A 2022 double-blind, placebo-controlled crossover study by Thurston, Hunjan, and colleagues in the Journal of Clinical Investigation (N=31 premenopausal women with HSDD) administered bremelanotide 1.75 mg SC at two study visits with fMRI scanning at each session to evaluate the drug's central mechanism. MC4R agonism significantly enhanced cerebellar and supplementary motor area activation in response to erotic visual stimuli compared with placebo (Z=2.3, P<0.05), deactivated the secondary somatosensory cortex, and increased amygdala-insula functional connectivity (F(1,30)=5.55, P=0.025). The authors interpreted this as bremelanotide reducing the cognitive-emotional barriers to sexual engagement rather than simply amplifying a peripheral signal. This mechanism helps explain why bremelanotide may be effective in women whose low desire is rooted in inhibitory rather than purely physiological factors.
4. Erectogenic Effects in Men (Preclinical and Early-Phase Data)
Two early-phase RCTs examined PT-141 in male populations. Diamond, Earle, and colleagues published a 2004 double-blind, placebo-controlled study in the International Journal of Impotence Research evaluating intranasal PT-141 at doses up to 20 mg in 32 healthy males (without visual sexual stimulation) and in men with mild-to-moderate erectile dysfunction (with visual sexual stimulation), finding a statistically significant erectogenic response on RigiScan at doses greater than 7 mg, with onset of the first erection occurring in approximately 30 minutes and the 20 mg dose producing significantly greater duration of base rigidity of 80% or above compared to placebo. Rosen, Diamond, and colleagues published a separate 2004 double-blind, placebo-controlled crossover study in the same journal evaluating subcutaneous PT-141 at doses ranging from 0.3 to 10 mg in healthy males and at 4 mg and 6 mg in 25 men with erectile dysfunction who achieved erections suitable for penetration 50% or less of the time on 100 mg sildenafil, finding that mean duration of base rigidity at 80% or above was 14 minutes at the 4 mg dose and 17 minutes at the 6 mg dose compared with 2 minutes for placebo on RigiScan over a single-dose session. A 2006 double-blind, placebo-controlled crossover study by Diamond, Earle, and colleagues published in the Journal of Sexual Medicine enrolled 18 premenopausal women with female sexual arousal disorder who each received a single intranasal dose of 20 mg bremelanotide or placebo at two in-clinic sessions, finding that significantly more women reported moderate or high sexual desire after bremelanotide versus placebo (P=0.01) and that among those who attempted intercourse within 24 hours, significantly more were satisfied with their level of arousal after bremelanotide (P=0.03). These trials support the biological plausibility of bremelanotide for male sexual dysfunction, but no Phase 3 trials in men have been conducted. Bremelanotide is not FDA-approved for any indication in men. No other uses have been approved by the FDA for bremelanotide, and its safety and efficacy for any use other than HSDD in premenopausal women have not been established through adequate and well-controlled clinical trials reviewed by the FDA.
5. Sexual Desire in Women With Female Sexual Arousal Disorder
A dose-finding RCT published by Clayton, Althof, and colleagues in Women's Health in 2016 randomized 327 premenopausal women with female sexual dysfunctions to placebo or subcutaneous bremelanotide at 0.75 mg, 1.25 mg, or 1.75 mg as needed over 12 weeks. For the pooled 1.25/1.75 mg doses versus placebo, mean changes from baseline were +0.7 versus +0.2 satisfying sexual events per month (P=0.02), +3.6 versus +1.9 on the FSFI total score (P=0.002), and −11.1 versus −6.8 on the FSDS-DAO total score (P=0.001), with nausea, flushing, and headache as the most common adverse effects. This study established the dose-response relationship that informed the Phase 3 protocol. A preclinical CNS mechanism review published by Pfaus and Giuliano in the Journal of Sexual Medicine in 2007 provided foundational context on how bremelanotide selectively increases sexual solicitation through a central, not peripheral, mechanism — a distinction relevant to understanding how it differs from PDE5 inhibitors in both mechanism and patient population.
PT-141 vs. PDE5 Inhibitors (Viagra/Cialis): Key Differences
Bremelanotide activates brain-based melanocortin receptors; PDE5 inhibitors (sildenafil, tadalafil) act peripherally on vascular smooth muscle. This is a mechanistic distinction with direct clinical implications.
PDE5 inhibitors work by preventing the breakdown of cyclic GMP (cGMP) in smooth muscle cells, which sustains vasodilation and blood flow to genital tissues. They require sexual arousal to be present and operate primarily on the vascular response to desire. They address the physical mechanics of erection or engorgement — not the desire signal that precedes them. Bremelanotide acts on the central nervous system, specifically on the melanocortin pathway in the hypothalamus and limbic system, where sexual motivation is generated. It modulates desire and arousal as neural phenomena, not blood flow events. A comprehensive review published by Edinoff, Sanders, and colleagues in Neurology International in 2022 confirmed this mechanistic distinction in a full account of bremelanotide's pharmacology.
The practical implication is that the two compound classes address different components of sexual dysfunction. PDE5 inhibitors are appropriate when the dysfunction is primarily vascular (impaired engorgement or erection despite normal desire). Bremelanotide is indicated for low desire as the primary complaint, where blood flow is not the limiting factor. a 2025 review in Expert Opinion on Pharmacotherapy by Ila and Pozzi reviewed the landscape of peptides for erectile dysfunction, noting that compounds acting through distinct mechanisms from PDE5 inhibitors are particularly relevant for patients who do not respond to that class or whose dysfunction is desire-based. Cross-compound comparisons should be interpreted with attention to the specific populations, endpoints, and study designs involved.
Biomarkers to Monitor With Bremelanotide
A licensed provider will determine appropriate monitoring. Bremelanotide's primary action is central nervous system-based, which means the monitoring focus is on cardiovascular safety, hormonal context, and general metabolic baseline rather than a single primary biomarker. The following are clinically relevant:
- Blood pressure (resting): Bremelanotide is associated with small, transient increases in blood pressure following administration, as documented in a 2017 randomized, double-blind, placebo-controlled ambulatory monitoring study by White and Myers in the Journal of Hypertension (N=397 premenopausal women; bremelanotide 0.75, 1.25, or 1.75 mg SC). The 1.75 mg dose produced a mean systolic increase of approximately 3 mmHg versus placebo in the 0-to-4-hour post-dose window, resolving within 12 hours, accompanied by a compensatory heart rate reduction of approximately 4.7 bpm. Pre-existing hypertension is a contraindication to use. Providers evaluate blood pressure at baseline and may advise against use in individuals with poorly controlled or uncontrolled hypertension.
- Estradiol: Bremelanotide is FDA-approved specifically for premenopausal women. Baseline estradiol status is relevant to clinical context — providers use hormonal baseline to confirm premenopausal status and to rule out hormonal causes of low desire (such as early perimenopause) that might warrant a different approach.
- Total and free testosterone: Low testosterone is associated with reduced sexual desire in both women and men. Baseline testosterone helps providers understand whether a hormonal deficit is contributing to HSDD alongside or independently of melanocortin pathway dysfunction. This is particularly relevant in women with low desire associated with surgical menopause or hormonal contraception.
- Prolactin: Elevated prolactin (hyperprolactinemia) is a recognized endocrine cause of low libido and sexual dysfunction in both sexes. Prolactin assessment at baseline rules out a treatable endocrine cause before attributing low desire to HSDD.
- SHBG (sex hormone binding globulin): SHBG modulates the bioavailability of sex hormones including testosterone and estradiol. Elevated SHBG reduces free hormone levels and can contribute to low desire independently of total hormone levels. SHBG is commonly evaluated alongside testosterone and estradiol in the hormonal workup for sexual dysfunction.
- Complete metabolic panel (CMP): Covers liver and kidney function. Relevant to baseline safety assessment for any prescription compound. Nausea is among the most common bremelanotide adverse effects and may prompt GI-focused monitoring in some individuals.
- TSH (thyroid-stimulating hormone): Thyroid dysfunction (both hypothyroidism and hyperthyroidism) can impair sexual function through multiple pathways including fatigue, mood disruption, and hormonal interference. Ruling out thyroid abnormality is standard in a comprehensive sexual dysfunction workup.
Blood pressure, estradiol, total testosterone, and prolactin are the core markers for a comprehensive hormonal and cardiovascular baseline before bremelanotide therapy. Establishing these baselines helps identify treatable endocrine causes of low desire, confirms candidacy, and supports individualized clinical decision-making. A provider will determine the appropriate scope of baseline testing. Relevant biomarkers for libido and hormonal balance extend beyond a single marker.
What Bremelanotide Is Typically Prescribed For
Bremelanotide (Vyleesi) is FDA-approved for the treatment of HSDD in premenopausal women. Providers evaluate candidates based on a clinical diagnosis of HSDD, defined as persistently low sexual desire causing personal distress, not attributable to a co-existing medical condition, psychiatric disorder, relationship problem, medication effect, or hormonal abnormality that would explain the symptom more parsimoniously. Key evaluation criteria include a full sexual function history, hormonal baseline (estradiol, testosterone, prolactin, SHBG), thyroid function, and a review of medications that may suppress desire (including certain antidepressants, hormonal contraceptives, and antihypertensives). Bremelanotide requires a prescription from a licensed provider. Superpower facilitates access through its licensed provider network and compounding pharmacy partners.
Who Should Not Use Bremelanotide
A licensed provider will evaluate individual risk factors before prescribing. The following are contraindications or conditions requiring additional clinical scrutiny, based on the Vyleesi FDA prescribing information and published safety data:
- Uncontrolled hypertension or known cardiovascular disease — bremelanotide causes transient blood pressure increases that may be clinically significant in individuals with pre-existing cardiovascular risk
- High cardiovascular risk profile (multiple risk factors for major adverse cardiovascular events) — the prescribing information advises against use in this population due to the transient hemodynamic effects
- Postmenopausal women — bremelanotide is FDA-approved only for premenopausal women with HSDD; it has not been studied for efficacy and safety in postmenopausal populations
- Pregnancy or breastfeeding — safety has not been established; women who could become pregnant should use contraception during bremelanotide use
- Known hypersensitivity to bremelanotide or any component of the Vyleesi formulation
- Concurrent use of oral naltrexone — bremelanotide may significantly reduce the systemic exposure of orally administered naltrexone by slowing gastric motility, potentially compromising naltrexone therapy in patients being treated for alcohol or opioid dependence
- Individuals who require consistent blood pressure control for cardiovascular management — the transient BP elevation may complicate management
A licensed provider will evaluate individual risk factors, medication interactions, and hormonal status before prescribing bremelanotide.
Side Effects and Safety Considerations
Bremelanotide's safety profile is well-characterized through the RECONNECT Phase 3 trials (N=1,267) and the 52-week open-label extension. Most adverse effects are dose-dependent and time-limited, resolving within hours of administration.
Common (reported in clinical studies):
- Nausea — the most frequently reported adverse effect; occurred in 40.0% of bremelanotide 1.75 mg recipients versus 1.3% on placebo in the Phase 3 RECONNECT trials (N=1,247 safety population) and in 40.4% of participants (N=684) in the 52-week open-label extension; typically onset within 30 minutes of dosing with a median duration of 2.4 hours; approximately 98% of cases were mild to moderate in severity
- Flushing — transient warmth or redness, particularly of the face; generally mild
- Injection-site bruising, pain, or erythema — common with subcutaneous administration; typically resolves within hours
- Headache — reported in approximately 9% of bremelanotide 1.75 mg recipients versus 5.6% on placebo in the Phase 3 RECONNECT trials (N=1,267)
Less common but reported:
- Transient blood pressure increase — in a randomized ambulatory monitoring study of 397 premenopausal women by White and Myers, bremelanotide 1.75 mg produced a mean systolic increase of approximately 2.5 to 3 mmHg versus placebo with peak effect in the 0-to-4-hour post-dose window, resolving within 12 hours; more pronounced in some individuals; contraindicated in uncontrolled hypertension (contact provider if blood pressure measurements are persistently elevated)
- Hyperpigmentation of the face, breasts, and gums with chronic use — related to bremelanotide's melanocortin receptor activity at MC1R (which governs pigmentation); risk increases with frequent use; the prescribing information limits use to no more than 8 doses per month to reduce hyperpigmentation risk, with no more than one dose per 24 hours
- Vomiting — associated with the nausea response in some patients; an antiemetic taken prior to bremelanotide may be considered per provider guidance
Is Bremelanotide Legal?
As of April 2026, bremelanotide is FDA-approved as Vyleesi (1.75 mg subcutaneous injection) for HSDD in premenopausal women. No other uses have been approved by the FDA. The safety and efficacy of bremelanotide for any use other than the approved HSDD indication in premenopausal women have not been established through adequate and well-controlled clinical trials reviewed by the FDA.
Bremelanotide is also available as a compounded formulation through licensed 503A compounding pharmacies with a patient-specific prescription from a licensed provider. The FDA-approved Vyleesi product and compounded bremelanotide are distinct from one another in terms of regulatory oversight: Vyleesi is subject to full FDA manufacturing standards; compounded bremelanotide is prepared under Section 503A compounding law. Superpower facilitates access to both through its licensed provider network.
Bremelanotide is not on the 2026 WADA Prohibited List by name. Athletes subject to anti-doping testing should nonetheless consult their governing body or a qualified anti-doping advisor, as WADA's prohibited list includes broad catch-all categories for peptides and peptide hormones that may encompass melanocortin agonists.
Understanding Your Baseline Before Starting Bremelanotide
Sexual dysfunction has multiple contributing causes, and hormonal and endocrine abnormalities can present identically to primary HSDD. Establishing a baseline that includes estradiol, testosterone, prolactin, SHBG, and thyroid function before starting bremelanotide is clinically important for two reasons: it rules out treatable endocrine causes that may respond to a different approach, and it provides a reference point for evaluating response over time. Blood pressure confirmation at baseline is essential given bremelanotide's transient hemodynamic effects.
That principle — test first, then decide — is central to Superpower's approach to preventive health: the belief that every clinical decision should be grounded in what your bloodwork actually shows, not in symptoms alone. Understanding your hormonal baseline is the first step.
Frequently Asked Questions
How does PT-141 work differently from Viagra?
Bremelanotide (PT-141) activates melanocortin receptors in the hypothalamus and limbic system to modulate sexual desire as a brain-based signal. Viagra (sildenafil) inhibits PDE5 in vascular smooth muscle to maintain blood flow to genital tissue. Bremelanotide targets desire and arousal centrally; sildenafil targets the physical vascular response to desire. They act on different systems, address different components of sexual function, and are used in different patient populations.
Can women use PT-141?
Yes. Bremelanotide is FDA-approved specifically for use in premenopausal women with hypoactive sexual desire disorder (HSDD). The pivotal RECONNECT Phase 3 trials were conducted exclusively in premenopausal women (N=1,267). The compound has also been studied in early-phase trials for female sexual arousal disorder. Bremelanotide is not FDA-approved for use in postmenopausal women.
How quickly does PT-141 take effect?
Bremelanotide is typically administered subcutaneously 45 minutes before anticipated sexual activity, based on the pharmacokinetic profile established in the RECONNECT trials. Peak plasma concentrations occur approximately 1 hour after subcutaneous injection. Individual onset may vary. The compound should not be administered more than once per 24-hour period.
What are the side effects of PT-141?
The most common side effects reported in the RECONNECT Phase 3 trials were nausea (approximately 40% of recipients), flushing, headache, and injection-site reactions. A transient increase in blood pressure occurs within 12 hours of injection in most users and resolves within 12 hours. Hyperpigmentation of the face, breasts, and gums has been reported with chronic or frequent use. Vomiting occurred in a subset of those who experienced nausea.
Is PT-141 FDA-approved?
Bremelanotide is FDA-approved as Vyleesi (1.75 mg subcutaneous injection) for HSDD in premenopausal women. This is the only FDA-approved indication. It has not been approved for use in men or in postmenopausal women. Compounded bremelanotide is also available through licensed 503A pharmacies with a patient-specific prescription, and is distinct from the FDA-approved Vyleesi product in terms of regulatory oversight.
Can you get PT-141 without a prescription?
No. Bremelanotide is a prescription-only compound in all its forms. Vyleesi requires a prescription from a licensed provider. Compounded bremelanotide also requires a patient-specific prescription from a licensed provider and is dispensed only by licensed 503A compounding pharmacies. It is not available over the counter. Superpower facilitates access through its licensed provider network and compounding pharmacy partners.
What is the difference between Vyleesi and compounded bremelanotide?
Vyleesi is the FDA-approved brand-name product (1.75 mg subcutaneous injection) manufactured under full FDA quality and manufacturing standards. Compounded bremelanotide is prepared by licensed 503A compounding pharmacies under Section 503A of the Federal Food, Drug, and Cosmetic Act, with a patient-specific prescription. The two have the same active compound but differ in regulatory oversight, manufacturing standards, and potentially in available doses or formulation options. A licensed provider can advise on which form is appropriate for a given clinical situation.
IMPORTANT SAFETY INFORMATION
Bremelanotide is FDA-approved as Vyleesi for hypoactive sexual desire disorder (HSDD) in premenopausal women. Compounded PT-141 (bremelanotide) is NOT the FDA-approved product and has not been reviewed by the FDA for safety or efficacy. Compounded PT-141 may only be dispensed upon a prescriber's patient-specific determination that a change from the FDA-approved Vyleesi product is clinically necessary. Superpower is a technology platform; Superpower does not prescribe or dispense medications.
Contraindications: uncontrolled hypertension or cardiovascular disease; postmenopausal women (not studied); pregnancy or breastfeeding; concurrent use of oral naltrexone.
Warnings: transient blood pressure increase (~3 mmHg systolic, resolving within 12 hours); nausea (reported in 40% of clinical trial participants); hyperpigmentation risk with frequent use (max 8 doses/month).
Common side effects: nausea, flushing, headache, injection site reactions.
Full prescribing information on the FDA-approved product (Vyleesi) at dailymed.nlm.nih.gov.
.avif)
.avif)
.avif)
.avif)
.avif)
.jpg)
.avif)
